The toxicity profile was appropriate with common non laboratory negative effects being nausea, vomiting, febrile neutropenia, diarrhea, rash and fatigue. Two consecutive European studies of 106 patients similarly reviewed clofarabine reversible Chk inhibitor as single agent induction therapy for patients over age 70 or ages 60 C69 with ECOG Performance Status. 2 or patients 65 years unfit for intensive chemotherapy. The rate of CR/CRi was 48-hours and, just like CLASSIC II benefits, responses rates didn’t change by cytogenetic risk group. However, survival in those two trials was shorter, with median OS for the entire cohort of 19 weeks. Those in CR and CRi had longer survival, 30 weeks and 47 weeks respectively. Clofarabine in addition has been studied in combination with Ara C in untreated older patients. A phase II study in untreated AML patients aged 50 and older used a regimen of clofarabine given at 40 mg/m2/ day 5 days and Ara C at 1 g/m2/day 5 days accompanied by additional cycles according to reaction. Price of CR/CRi was 60-minute with unusual grade 3/4 toxicities. Comparison to historical controls, however, showed no survival advantage Eumycetoma regardless of the higher CR rate. Median survival for your all patients was 10. A few months, and for all those obtaining CR was 23. 5 months. 45 Research of lower dose treatment compared treatment with clofarabine with or without low dose Ara C using an adaptive randomization approach. Most patients received the combination regime. Notably higher CR rates were seen with the combination. There clearly was no difference in overall survival. The results of the above mentioned studies suggest a role for clofarabine in AML induction and continuing studies will examine the efficiency of clofarabine in combination with different chemotherapy and novel agents. However, up to now there are no published results showing a survival benefit for clofarabine induction versus 7 3. C50 Strategies to Improve Remission Duration Despite morphologic and cytogenetic CR following induction Tipifarnib price and consolidation treatment, patients who do not obtain extra chemotherapy following induction will relapse, usually within 6 to 9 months. Chemotherapy based consolidation might prolong remission duration, nevertheless, many patients with AML will relapse within 2 C3 years. A minority of people are cured with chemotherapy alone, and the others are cured with stem-cell transplantation. Long term survival for elderly patients and those with poor chance cytogenetics is dismal, and various strategies have been studied in the post remission setting in a attempt to prolong remission duration. Maintenance therapy for AML remains an area of active research, although there is a proven part for post remission therapy for other hematologic malignancies including multiple myeloma, acute promyelocytic leukemia and acute lymphocytic leukemia.